ReviewCirculation. Population health and outcomes2026
Artificial Intelligence in Peripheral Artery Disease: A Science Advisory From the American Heart Association.
Review in Circulation. Population health and outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Artificial intelligence shows promise for improving care for peripheral artery disease through earlier detection, improved risk stratification, more tailored treatment planning, and more efficient care delivery. This American Heart Association science advisory reviews the current and emerging applications of artificial intelligence across the peripheral artery disease care continuum, including population-level screening, imaging diagnostics, outcome prediction, aneurysm risk estimation, and surgical planning. Machine learning and deep learning models demonstrate strong performance in automating peripheral artery disease detection from structured and unstructured electronic health record data, predicting major adverse cardiovascular and limb events, and enhancing diagnostic accuracy through advanced imaging analysis. Multimodal models that integrate clinical, genetic, behavioral, and biomarker data further enhance predictive precision and support individualized care strategies. Despite these advancements, real-world implementation of artificial intelligence in peripheral artery disease remains limited because of challenges in clinician training, regulatory clarity, data governance, and equitable access. We outline key barriers to adoption and propose strategies to address professional, legal, and ethical concerns, including mitigating bias and leveraging implementation frameworks. Ensuring the trustworthy, fair, and effective integration of artificial intelligence into vascular care will require interdisciplinary collaboration, ongoing validation, and robust oversight. This science advisory serves as a guide for clinicians, researchers, and policymakers on the responsible deployment of artificial intelligence in the diagnosis and management of peripheral artery disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.